KalVista Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
KalVista Pharmaceuticals has a total shareholder equity of $88.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $114.0M and $25.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$75.59m |
| Equity | US$88.58m |
| Total liabilities | US$25.39m |
| Total assets | US$113.97m |
Recent financial health updates
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Jan 30
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Oct 04We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
May 02Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
Sep 24Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
May 18Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth
Feb 02Recent updates
KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Feb 14We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Jan 30We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Oct 04We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
May 02KalVista: Another Setback But The Key Value Driver Is Still In Place
Oct 14Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
Sep 24KalVista Pharmaceticals GAAP EPS of -$0.94
Sep 08KalVista reaches five-month high as rival tumbles on hereditary angioedema
Aug 22KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11
Jul 07Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
May 18Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth
Feb 02We Discuss Why KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Compensation May Be Closely Reviewed
Sep 24We're Hopeful That KalVista Pharmaceuticals (NASDAQ:KALV) Will Use Its Cash Wisely
Jul 02KalVista Pharma's oral KVD900 shows rapid improvement in HAE attacks in mid-stage study
Jun 07KalVista Pharmaceuticals names new medical chief
May 03How Much Did KalVista Pharmaceuticals' (NASDAQ:KALV) CEO Pocket Last Year?
Mar 01Estimating The Fair Value Of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
Feb 03
Financial Position Analysis
Short Term Liabilities: KALV's short term assets ($104.1M) exceed its short term liabilities ($19.1M).
Long Term Liabilities: KALV's short term assets ($104.1M) exceed its long term liabilities ($6.3M).
Debt to Equity History and Analysis
Debt Level: KALV is debt free.
Reducing Debt: KALV has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KALV has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: KALV is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.